Baxter International Inc (BAX)

Currency in USD
28.56
+1.05(+3.82%)
Closed·
After Hours
28.59+0.03(+0.11%)
·
BAX Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 7 days
Fair Value
Day's Range
27.9228.71
52 wk Range
26.2540.49
Key Statistics
Prev. Close
27.51
Open
28.09
Day's Range
27.92-28.71
52 wk Range
26.25-40.49
Volume
6.78M
Average Volume (3m)
4.01M
1-Year Change
-18.97%
Book Value / Share
13.81
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.03
Upside
+33.16%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Baxter International Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Baxter International Inc Company Profile

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc SWOT Analysis


Healthcare Titan
Baxter International, a $17.85B market cap leader in medical supplies, boasts a 55-year dividend streak amid industry shifts
Analyst Optimism
Barclays reinstates Overweight rating with $39 price target, signaling renewed confidence in Baxter's market outperformance potential
Financial Resilience
EPS projections show growth from $2.50 in FY2025 to $2.28 in FY2, with analysts predicting a return to profitability despite recent challenges
Strategic Positioning
Baxter navigates regulatory hurdles and competitive pressures while capitalizing on aging populations and emerging markets for sustained growth
Read full SWOT analysis

Baxter International Inc Earnings Call Summary for Q1/2025

  • Baxter International beats Q1 2025 expectations with adjusted EPS of $0.55 and revenue of $2.63 billion, surpassing forecasts
  • Adjusted operating margin improved to 14.9%, up 260 basis points year-over-year, driven by operational efficiency
  • Full-year 2025 guidance remains strong with projected sales growth of 7-8% and adjusted EPS between $2.47 and $2.55
  • Stock rose 1.24% post-announcement; company plans inorganic investments and share buyback program
  • Anticipated tariffs could impact financials by $60-$70 million in 2025; company focuses on cost containment strategies
Last Updated: 01/05/2025, 14:46
Read Full Transcript

Compare BAX to Peers and Sector

Metrics to compare
BAX
Peers
Sector
Relationship
P/E Ratio
−52.9x−33.6x−0.5x
PEG Ratio
0.420.530.00
Price/Book
2.1x2.6x2.6x
Price / LTM Sales
1.4x1.9x3.2x
Upside (Analyst Target)
29.0%1,621.5%41.9%
Fair Value Upside
Unlock7.5%4.3%Unlock

Analyst Ratings

6 Buy
11 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 38.03
(+33.16% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.54%
Dividend Yield
2.38%
Industry Median 1.34%
Annualised payout
0.68
Paid quarterly
5-Years Growth
+0.89%
Growth Streak

Earnings

Latest Release
May 01, 2025
EPS / Forecast
0.55 / 0.48
Revenue / Forecast
2.63B / 2.59B
EPS Revisions
Last 90 days

BAX Income Statement

People Also Watch

568.50
NOC
+0.84%
29.42
CNC
+5.49%
117.26
LEN
-1.07%
224.03
LULU
+0.04%
48.98
BMY
+2.00%

FAQ

What Stock Exchange Does Baxter Trade On?

Baxter is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Baxter?

The stock symbol for Baxter is "BAX."

What Is the Baxter Market Cap?

As of today, Baxter market cap is 14.68B.

What Is Baxter's Earnings Per Share (TTM)?

The Baxter EPS (TTM) is -0.54.

When Is the Next Baxter Earnings Date?

Baxter will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is BAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Baxter Stock Split?

Baxter has split 4 times.

How Many Employees Does Baxter Have?

Baxter has 38000 employees.

What is the current trading status of Baxter (BAX)?

As of 24 Jul 2025, Baxter (BAX) is trading at a price of 28.56, with a previous close of 27.51. The stock has fluctuated within a day range of 27.92 to 28.71, while its 52-week range spans from 26.25 to 40.49.

What Is Baxter (BAX) Price Target According to Analysts?

The average 12-month price target for Baxter is USD38.03, with a high estimate of USD55 and a low estimate of USD27. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +33.16% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.